S. Pearson

发表

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

A. Rabow, D. M. Andrews, G. Walker, 2015, Journal of medicinal chemistry.

Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.

Jon Winter, David Whittaker, Gareth Davies, 2012, Journal of medicinal chemistry.

Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors.

Rhys D O Jones, S. Guichard, W. Shao, 2018, Journal of medicinal chemistry.

Running title : Pharmacology of SERD inhibitor in breast cancer models

Graham, A. Rabow, R. A. Norman, 2016 .

A Practical, Efficient Synthesis of 5-Amino-7-azaindole

S. Pearson, S. Nandan, 2005 .

Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.

B. Barlaam, P. Macfaul, S. Pearson, 2018, ACS medicinal chemistry letters.

Studies on Pd/imidazolium salt protocols for aminations of aryl bromides and iodides using lithium hexamethyldisilazide (LHMDS)

S. Caddick, James S. Scott, S. Pearson, 2005 .

A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

James S. Scott, B. Barlaam, R. Ducray, 2008, Bioorganic & medicinal chemistry letters.

Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

James S. Scott, B. Barlaam, R. Bradbury, 2007, Bioorganic & Medicinal Chemistry Letters.

Development of a practical Buchwald-Hartwig amine arylation protocol using a conveniently prepared (NHC)Pd(R-allyl)Cl catalyst.

Richard J. Fitzmaurice, S. Caddick, James S. Scott, 2008, Organic & biomolecular chemistry.

Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.

Peter Ballard, Andrew G. Leach, Jason G Kettle, 2013, Journal of medicinal chemistry.

Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.

J. Kendrew, R. Bradbury, P. Ballard, 2006, Bioorganic & medicinal chemistry letters.

Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2.

C. A. Roberts, J. Culshaw, G. Currie, 2015, Journal of medicinal chemistry.

Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.

R. Anjum, Yafeng Xue, James S. Scott, 2020, Bioorganic & medicinal chemistry.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

A. Rabow, G. Walker, R. A. Norman, 2016, Cancer research.

Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors.

Nichola L. Davies, Yafeng Xue, James S. Scott, 2022, Bioorganic & medicinal chemistry.